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Abstract. 
 
p53 is mutated in 
 
z
 
50% of human cancers, 
whereas mutations of the related p73 gene are rare. p73 
can activate p53-responsive promoters and induce
apoptosis when overexpressed in certain p53-deﬁcient 
tumor cells. We show that p73 isoforms, p73
 
a
 
 and p73
 
b
 
, 
can each induce permanent growth arrest with markers 
of replicative senescence when overexpressed in a tet-
racycline-regulatable manner in human cancer cells 
lacking functional p53. Human homologue of mouse 
double minute 2 gene product (hMDM2), but not an 
NH
 
2
 
-terminal deletion mutant, coimmunoprecipated 
with p73
 
a
 
 or p73
 
b
 
, and inhibited p73 transcriptional ac-
tivity as with p53. In contrast to p53, ectopically ex-
pressed hemagglutinin (HA)-tagged p73 proteins were 
not stabilized by treatment with several DNA damag-
ing agents. Furthermore, unlike normal p53, which in-
creases in response to DNA damage due to enhanced 
protein stability in MCF7 cells, endogenous p73 protein 
levels were not increased in these cells under the same 
conditions. Thus, although p73 has an ability, compara-
ble to that of p53, to suppress tumor cell growth in p53-
deﬁcient cells, p73 induction is regulated differently 
from p53. These ﬁndings suggest that the selective pres-
sures for p53 rather than p73 inactivation in tumors 
may reﬂect their differential responses to stresses such 
as DNA damage, rather than their capacities to induce 
permanent growth arrest or apoptosis programs.
Key words: p53 • p73 • tumor suppression • replica-
tive senescence • DNA damage
 
T
 
HE
 
 p53 gene is the most frequently inactivated tu-
mor suppressor identified in human tumors. Ap-
proximately 50% of all human cancers lack a wild-
type p53 allele, and thus fail to produce a normal version
of the p53 protein (Nigro et al., 1989; Harris and Hollstein,
1993; Hollstein et al., 1994; Levine et al., 1995). Wild-type
p53 limits cellular proliferation by inducing either a tran-
sient cell cycle block, apoptosis, or senescence, depending
on the cellular context (Levine, 1997). These activities
have been linked to the ability of p53 to bind to specific
DNA sequences and activate transcription (Gottlieb and
Oren, 1996; Ko and Prives, 1996; Levine, 1997). The p53
protein accumulates dramatically in response to genotoxic
stress induced by DNA damage, hypoxia, and depletion of
ribonucleotide triphosphate pools (Levine, 1997). The in-
duction of p53 is mainly regulated at the level of protein
stability. p53 is both neutralized and degraded by the
mouse double minute 2 gene product ([MDM2]
 
1
 
 oncopro-
tein) (human homologue of MDM2 [hMDM2] in human)
(Momand et al., 1992; Oliner et al., 1993; Haupt et al.,
1997; Kubbutat et al., 1997), which itself is a p53 target
gene.
Recently, several members of the p53 family have been
identified (Jost et al., 1997; Kaghad et al., 1997; Osada et
al., 1998; Trink et al., 1998; Yang et al., 1998). One mem-
ber, p73, has been shown to encode two differently spliced
products, p73
 
a
 
 and p73
 
b
 
. p73
 
b
 
, which is 499 amino acids
(aa) in length with a unique pentamer at its extreme
COOH terminus, is 137 aa shorter than p73
 
a
 
, which has
636 aa. In addition, p73 not only shares a high degree of
similarity with p53 in primary sequence (
 
z
 
60% identity in
the core DNA binding domain, 29% identity in NH
 
2
 
-ter-
minal transactivation domain, and 42% identity in the
COOH-terminal oligomerization domain), but also seems
to exhibit similar functions. Like p53, both p73
 
a
 
 and p73
 
b
 
can bind to DNA and activate transcription (Jost et al.,
1997; Marin et al., 1998; Zhu et al., 1998). It is currently
unknown whether these proteins bind to DNA as homo-
oligomers or heterooligomers. However, it has been re-
ported that p73
 
b
 
 can bind to itself and bind weakly to
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9
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p73
 
a
 
 in yeast two-hybrid assays (Kaghad et al., 1997).
When overproduced, both p73
 
a
 
 and p73
 
b
 
 can block cell
proliferation and induce apoptosis in cells, irrespective of
their p53 status (Jost et al., 1997; Kaghad et al., 1997).
It is well-established that oncoproteins encoded by cer-
tain DNA tumor viruses inhibit the function of p53 (Fields
et al., 1996). The adenovirus E1B 55-kD (Yew and Berk,
1992; Debbas and White, 1993) protein and SV-40 T anti-
gen (Lane and Crawford, 1979; Linzer and Levine, 1979;
Bargonetti et al., 1992; Mietz et al., 1992; Jiang et al., 1993)
bind to p53 and sequester it in an inactive complex. The
human papillomavirus E6 protein interacts with p53 and
promotes its ubiquitin-dependent degradation (Scheffner
et al., 1990; Werness et al., 1990; Mietz et al., 1992; Band et
al., 1993; Hoppe-Seyler and Butz, 1993). However, none
of these viral oncoproteins appear to interact with p73
(Marin et al., 1998; Roth et al., 1998). Unlike p53, which is
widely mutated in human cancers, to date intragenic p73
mutations have been identified in only three lung cancer
cell lines (Yoshikawa et al., 1999). In this report, we devel-
oped a tetracycline (tet)-regulatable system for p73 over-
expression in human EJ bladder cancer cells in order to
compare the regulation and effector functions of these re-
lated proteins in tumor cells that selectively lost p53 func-
tion in the course of their evolution.
 
Materials and Methods
 
Cell Culture
 
The EJ human bladder carcinoma cell line, 293T human embryonic kid-
ney cell line, and MCF7 human breast carcinoma cell line were main-
tained in DMEM supplemented with 10% FBS (GIBCO BRL). H1299
human lung carcinoma cells were maintained in RPMI 1640 supplemented
with 10% FBS. Both EJ-p53 and EJ-p73 cells were maintained in DMEM
supplemented with 10% FBS, penicillin-streptomycin (50 U/ml), hygro-
mycin (100 
 
m
 
g/ml), and geneticin (750 
 
m
 
g/ml). To repress the expression
of p73
 
a
 
, p73
 
b
 
, or p53, tet was added to the medium every 3 d to a final
concentration of 1 
 
m
 
g/ml. To induce p73 expression, cells were washed
three times with PBS and seeded directly in culture medium without tet.
 
Plasmid Construction and DNA Transfection
 
The NH
 
2
 
-terminal hemagglutinin (HA)-tagged coding sequence of p73
 
a
 
(or p73
 
b
 
) (obtained from M. Kaghad, Sanofi Recherche, Innopole,
France) was released with BamHI and StuI from pcDNA3-p73
 
a
 
 (or p73
 
b
 
)
and then ligated with pBluescript SK digested with BamHI and EcoRV.
The resulting plasmid pBluescript-p73
 
a
 
 (or p73
 
b
 
) was then digested with
BamHI and SalI, and the fragment encoding p73
 
a
 
 (or p73
 
b
 
) was cloned
downstream of the tet-regulated promoter into pUHD10-3 (generously
provided by H. Bujard, Universitat Heidelberg, Heidelberg, Germany),
resulting in plasmid pTet-p73
 
a
 
 (or p73
 
b
 
). EJ-tTA cells, generated as de-
scribed previously (Sugrue et al., 1997), were transfected with pTet-p73
 
a
 
(or p73
 
b
 
) using the standard calcium phosphate method. Transfectants
were doubly selected in the presence of hygromycin (100 
 
m
 
g/ml) and ge-
neticin (750 
 
m
 
g/ml). Individual clones of stable transfectants, designated
EJ-p73
 
a
 
 or EJ-p73
 
b
 
, were selected for further analysis.
 
Immunoblot Analysis
 
Cells cultured in the presence or absence of tet were washed twice with
ice-cold PBS with 2 mM sodium vanadate and lysed in EBC lysis buffer as
described previously (Fang et al., 1999). Lysates were cleared by centrifu-
gation at 14,000 rpm for 20 min at 4
 
8
 
C. Protein concentrations were deter-
mined using the BCA protein assay kit (Pierce). About 40 
 
m
 
g of cellular
protein per sample were subjected to 12 (for p73) or 7.5% (for hMDM2)
SDS-PAGE and transferred to Immobilon (Millipore) polyvinylidene dif-
luoride filter. p73 was detected using an HA polyclonal antibody (Santa
Cruz Biotechnology) or Ab-2 mAb (clone ER-15; NeoMarkers), and wild-
 
type as well as mutant hMDM2 were detected using Ab-1 mAb (Onco-
gene Science), followed by ECL detection system (Amersham Pharmacia
Biotech).
 
Immunoprecipitation Analysis
 
293T cells were transiently cotransfected with p73
 
a
 
 or p73
 
b
 
 and mdm2 us-
ing Fugene 6 (Boehringer Mannheim). Cell lysates were made using EBC
lysis buffer and 200 
 
m
 
g of cellular protein was incubated with HA or
MDM2 antibody at 4
 
8
 
C for 1 h, followed by another hour incubation with
protein A beads. Immunoprecipitation complexes were washed three
times with NET-N buffer (Fang et al., 1999), and subjected to SDS-PAGE
followed by immunoblot with the reciprocal antibody.
 
Senescence-associated 
 
b
 
-Galactosidase
(SA-
 
b
 
-gal) Staining
 
Cells were cultured in the presence or absence of tet for the indicated
times, washed in PBS, and fixed with 2% formaldehyde/0.2% glutaralde-
hyde in PBS for 5 min at room temperature. The method for senescence-
associated 
 
b
 
-galactosidase (SA-
 
b
 
-gal) (pH 6.0) staining was performed as
described (Dimri et al., 1995).
 
Cell Cycle Analysis
 
Subconfluent cultures were pulse labeled for 30 min with 10 
 
m
 
M 5-bromo-
2
 
9
 
-deoxyuridine (BrdU) (Sigma). Both adherent and floating cells were
harvested, fixed in 70% ethanol, and then double stained with fluorescein
isothiocyanate-conjugated anti-BrdU antibody (Becton Dickinson) and 5
 
m
 
g/ml propidium iodide (Sigma Chemical Co.). Cell cycle analysis was
performed on a fluorescence-activated cell sorter (FACScan; Becton
Dickinson). Data were analyzed using Elite software (Becton Dickinson).
 
Treatment with DNA Damaging Agents
 
EJ-p53, EJ-p73
 
a
 
, and EJ-p73
 
b
 
 cells were seeded in the presence of 2 ng/
ml tet to induce submaximal levels of either p53 or p73. Cells were then
treated with 2 or 5 
 
m
 
g/ml mitomycin C, 0.02 or 0.1 
 
m
 
g/ml doxorubicin, or 5
or 10 ng/ml actinomycin D for 24 h. MCF7 cells were treated under the
same condition. Cell lysates were prepared and aliquots containing 40 
 
m
 
g
of cell protein were subjected to SDS-PAGE followed by immunoblot
analysis with 1801 mAb for p53, HA polyclonal antibody, or ER-15 mAb
for p73.
 
Luciferase Assays
 
Plasmid DNA was transiently transfected into H1299 cells using Fugene 6
(Boehringer Mannheim). Approximately 2 
 
3
 
 10
 
6
 
 cells were cotransfected
with plasmids as indicated. Cells were harvested 48 h after transfection,
and luciferase activity was measured using a luciferase assay kit (Pro-
mega). The assay was normalized by cotransfection of a pCMV–
 
b
 
-gal
plasmid and measurement of 
 
b
 
-galactosidase activities.
 
Results
 
Inducible Expression of p73
 
a
 
 or p73
 
b
 
 in EJ Cells
 
It has been shown that p53 can induce growth arrest, apop-
tosis, or senescence depending on the cell context (Levine,
1997). Since p73 is a homologue of p53, we attempted to
examine the biological consequences of induced p73 over-
expression in EJ cells, which lack functional p53 due to a
mutation in exon 5 (Sharma et al., 1993; Rieger et al.,
1995). To obtain tightly regulated p73
 
a
 
 or p73
 
b
 
 expres-
sion, the tet-regulatable expression system (Gossen and
Bujard, 1992) was used. EJ-tTA cells, which contain the
transactivator with a hygromycin-resistant marker, were
transfected with either pTet-p73
 
a
 
 or pTet-p73
 
b
 
 containing
HA-tag and a neomycin-resistant marker. Stable clones
were isolated by double selection. More than 10 tet-regu-
latable clones for each gene were selected and two inde- 
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pendent clones were analyzed in detail. The phenotypes in
each case (designated EJ-p73
 
a
 
 or EJ-p73
 
b
 
) were similar.
As shown in Fig. 1 A, there was no detectable amount of
HA-p73
 
a
 
 in the presence of 1 
 
m
 
g/ml tet as determined by
immunoblot analysis (Fig. 1 A, lane 1). Within 24 h of tet
removal, p73
 
a
 
 was induced and became readily detectable
(Fig. 1 A, lane 2), with p73
 
a
 
 levels further increasing to a
steady-state level by 48 h (Fig. 1 A, lane 3). To test
whether p73
 
a
 
 induction was reversible, tet was added back
to the medium after induction for 24 h, and p73
 
a
 
 levels ex-
amined 24 h later. It was apparent that p73
 
a
 
 returned to
an undetectable level (compare lanes 6 and 2 in Fig. 1 A)
under these conditions, indicating that p73
 
a
 
 expression
was fully reversible. Similar results were obtained with EJ-
p73
 
b
 
 as shown in Fig. 1 B.
It can also been observed that two p53 transcriptional
target genes, p21 and mdm2, were induced by both p73
 
a
 
and p73
 
b
 
 (Fig. 1). The kinetics of the induction paralleled
that of p73, and was also reversible following readdition of
tet (Fig. 1, A and B, lanes 6).
 
p73 Induces Irreversible Growth Arrest Associated with 
Senescence-like Morphology
 
In response to p73 induction in EJ-p73
 
a
 
 or EJ-p73
 
b
 
 cells,
we observed profound alterations in both cell proliferative
capacity and morphology. Whereas EJ-p73 cells grew as
small, rounded, refractile cells in the presence of tet and
reached confluence, similar to parental EJ cells, the induc-
tion of p73 expression caused cells to stop growth and ex-
hibit increased size and flattened morphology as well as
enlarged nuclei (Fig. 2). Of note, there were no character-
istics of apoptosis detected in these cells as determined by
4
 
9
 
,6-diamidino-2
 
9
 
-phenylindole dihydrochloride nuclear stain-
ing (data not shown). To examine the reversibility of p73-
induced growth arrest in EJ cells, we performed a colony
formation assay. EJ-p73
 
a
 
 or EJ-p73
 
b
 
 cells were seeded at
about 100 cells per 60-mm plate and maintained in the ab-
sence of tet for varying time periods followed by tet read-
dition. Cultures were subsequently maintained in the pres-
ence of tet for another 2 wk, followed by fixation and
Giemsa staining. The number of colonies were counted
 
and plotted as shown in Fig. 3. Maintenance of the cells in
the absence of tet for three or more days resulted in a
marked reduction of the ability to form colonies. Indeed,
the kinetics of permanent inhibition of colony formation
by p73
 
a
 
 or p73
 
b
 
 was comparable to that observed with
p53 (Sugrue et al., 1997). These experiments demonstrated
that induced expression of either p73
 
a
 
 or p73
 
b
 
 in EJ cells
causes irreversible growth arrest.
 
Expression of p73 Induces G1 and G2 Cell Cycle Arrest
 
To investigate in which specific cell cycle stage(s) p73 ar-
rested EJ cells, we performed fluorescence-activated cell
sorting analysis using EJ-p73
 
a
 
 or EJ-p73
 
b
 
 cell. EJ-p73
cells were maintained in the presence or absence of tet for
varying time periods, followed by analysis using simulta-
neous flow cytometry for both DNA content and DNA
synthesis, with propidium iodide staining and BrdU label-
ing, respectively. After tet removal, EJ-p73 cells exhibited
a dramatic reduction in BrdU incorporation within 3 d,
with the population of S phase cells declining from 45.2
and 51.7% in (
 
1
 
) tet to 5.9 and 12.4% in (
 
2
 
) tet for EJ-
p73
 
a
 
 or EJ-p73
 
b
 
, respectively (Fig. 4). Conversely, the
percentage of cells in both G1 and G2/M phases increased
from 34.1 and 20.2% in (
 
1
 
) tet to 60.5 and 33.6% in (
 
2
 
)
tet for EJ-p73
 
a
 
, and from 31.5 and 16.0% in (
 
1
 
) tet to 56.3
and 26.5% in (
 
2
 
) tet for EJ-p73
 
b
 
 by 3 d, respectively.
Thus, induced expression of p73a or p73b arrested EJ cells
in both G1 and G2/M phases. Induction of both G1 and
G2/M arrest has also been observed with p53 overexpres-
sion in EJ-p53 cells (Sugrue et al., 1997). Of note, there
was no evidence of a sub-G1 population as usually seen in
apoptosis in either EJ-p73a or b cells.
Expression of a Senescence-specific Marker after
p73 Induction
It has been shown that senescent but not presenescent,
quiescent, or terminally differentiated cells express a SA-
b-gal, which can be detected by incubating cells at pH 6.0
with 5-bromo-4-chloro-3-indolyl b-D-galactoside (X-gal)
(Dimri et al., 1995). Since a striking feature of induced p73
expression was a morphological change characteristic of
senescent cells, we examined whether EJ-p73 cells ex-
pressed this senescent-specific marker after p73 induction.
As shown in Fig. 5, .90% of EJ-p73 cells became positive
for SA-b-gal staining within 7 d after induction of p73a or
p73b, whereas EJ-p73 cells grown in the presence of tet
over the entire time course of the experiment showed no
staining (only [1] tet 7 d of EJ-p73a is shown). These re-
sults indicated that expression of p73 can promote a senes-
cence-like program in EJ cells.
Wild-Type but Not NH2-Terminal Deleted hMDM2 
Interacts with p73a or p73b and Inhibits Their 
Transcriptional Activity
It has been reported that the product of mdm2, a p53 tran-
scriptional response gene, can interact with p53 and target
it for degradation (Haupt et al., 1997; Kubbutat et al.,
1997). Since p73 shares high homology with p53, we
sought to investigate whether mdm2 also interacted with
p73. 293T cells were cotransfected with p73a or p73b, to-
Figure 1. Tet regulation of p73a and p73b expression and induc-
tion of target genes in EJ-p73a (A) and EJ-p73b (B) cells. Immu-
noblot analysis of HA-tagged p73a and p73b as well as endoge-
nous p21 and mdm2 expression in (1) tet (lane 1) or (2) tet for 1 d
(lane 2), 2 d (lane 3), 3 d (lane 4), 4 d (lane 5), or in (2) tet for 1 d
followed by the addition of tet for 1 d (lane 6).The Journal of Cell Biology, Volume 147, 1999 826
gether with wild-type or a mutant human MDM2 with the
first 58 aa deleted (DN-hMDM2). This deletion is known
to abolish MDM2’s ability to interact with p53 (Brown et
al., 1993). Reciprocal coimmunoprecipitation was per-
formed using anti-mdm2 or HA antibody, followed by
Western blot analysis. As shown in Fig. 6 B, p73a or p73b
was detected in the immunocomplexes precipitated by the
anti-mdm2 antibody; similarly, hMDM2 was also detected
in the immunocomplexes precipitated by the anti-HA an-
tibody. However, there was no detectable p73a or p73b
associated with the mutant hMDM2; similarly, mutant
hMDM2 was not detected in the immunocomplexes asso-
ciated with p73a or p73b. These experiments demon-
strated that p73a and p73b interact with wild-type but not
NH2-terminal deleted hMDM2, despite the comparable
expression level of these proteins (Fig. 6 A).
Next, we attempted to investigate whether the interac-
tion between hMDM2 and p73 had any effects on p73’s
transcriptional activity. To do so, p73 or vector was co-
transfected into H1299 cells along with a luciferase re-
porter plasmid that contains the genomic sequence from
the p21 promoter. As shown in Fig. 7, p53, p73a, and p73b
increased the luciferase activity by 15-, 18-, and 38-fold
compared with vector, respectively. Neither hMDM2 nor
DN-hMDM2 alone had any effect on the luciferase activ-
ity. When wild-type mdm2 was cotransfected with p53,
p73a, or p73b, the luciferase activity decreased three-,
four-, and sixfold, respectively. However, when DN-
hMDM2 was cotransfected, there was no significant change
in the p21 promoter response. These experiments demon-
strated that wild-type hMDM2 interacts with p73 and spe-
cifically inhibits its transcriptional activation of the p21
promoter, consistent with recent reports (Balint et al.,
1999; Dobbelstein et al., 1999; Zeng et al., 1999).
p73 Is Not Induced at a Posttranslational Level by DNA 
Damaging Agents
It has been shown that p53 is induced by various stresses
such as DNA damage, hypoxia, or nucleotide pool deple-
tion (Ko and Prives, 1996; Levine, 1997), and this induc-
tion is mainly regulated at the level of p53 protein stability
(Haupt et al., 1997; Kubbutat et al., 1997). To investigate
whether p73 could also be stabilized by DNA damaging
Figure 2. Morphological changes induced by overexpression of p73a or p73b in EJ-p73a and EJ-p73b cells. EJ-p73a or EJ-p73b cells
were seeded directly in (1) tet or (2) tet medium at 105 cells per 100-mm plate. At day 2, 4, 6, and 8, cells were photographed using Ni-
kon Eclipse TE200 microscope (1003).Fang et al. Comparative Analysis of p73 and p53 827
agents, we titrated the amount of tet required to induce
moderate increases in tet-regulatable p53 or HA-p73 lev-
els, and treated the cells with different concentrations of
mitomycin C (MMC), doxorubicin (Dox.), or actinomycin
D (Act.D) to activate DNA damage checkpoints, followed
by immunoblot analysis with p53 or HA antibodies. As
shown in Fig. 8 A, p53 levels increased in response to each
DNA damaging agent, consistent with previous reports
(Di Leonardo et al., 1994; Nelson and Kastan, 1994). In
striking contrast, the levels of both p73a and p73b did not
increase after exposure to any of these DNA damaging
agents. Since the HA-tagged p73 was transcriptionally ac-
tive, it is unlikely that it would respond differently from
endogenous p73 to DNA damage, although we cannot ex-
clude this possibility. Thus, we next tested whether endog-
enous p73 behaved similarly.
MCF7 cells were treated with different concentrations
of DNA damaging agents, followed by immunoblot analy-
sis with p53 or p73 antibodies. As shown in Fig. 8 B, p53
levels increased after each treatment. However, the levels
of both p73a and p73b did not increase in response to any
of the DNA damaging agents tested. These results sug-
gested that unlike p53, p73 protein stability was not in-
creased in response to several different genotoxic agents.
Discussion
These studies demonstrate that in tumor cells lacking
functional p53, the induced overexpression of either p73a
or p73b, an alternative product of the p73 gene, promoted
a cellular response leading to irreversible growth arrest
with markers of replicative senescence. This conclusion is
supported by the following observations: induction of a
flattened, enlarged cell morphology, commonly observed
with senescent fibroblasts; and SA-b-gal staining (pH 6.0),
a specific biochemical marker of senescent cells (Dimri et
al., 1995). The commitment to senescence became irre-
versible within 3 d and no longer required p73 expression.
Similar results have been observed with overexpression of
p53 or p21, an effector of both p53 and p73, in these same
cells (Fang et al., 1999; Sugrue et al., 1997). p73 has been
reported to induce apoptosis when overexpressed in some
tumor cells, independent of p53 status (Jost et al., 1997;
Kaghad et al., 1997; Zhu et al., 1998). In our studies, there
were no findings consistent with apoptosis in response to
p73, p53, or p21 overexpression in any of the assays used
(Fang et al., 1999; Sugrue et al., 1997), suggesting that p73,
like p53, induces apoptosis in a cell context–dependent
manner.
We also found that p73 can induce mdm2 and p21, two
known transcriptional targets of p53, consistent with previ-
ous studies (Di Como et al., 1999; Zhu et al., 1998). It has
been shown that p53 interacts with the NH2-terminal 58 aa
of hMDM2, since removal of this segment abolishes this
interaction (Brown et al., 1993). Similarly, we showed that
hMDM2 coimmunoprecipitates with both p73a and p73b,
and this interaction was also disrupted by deletion of the
NH2-terminal 58 aa residues of hMDM2, indicating that
p73 interacts through the same NH2-terminal 58 residues.
We further observed that hMDM2 inhibited the transcrip-
tional response from the p21 promoter in response to p73,
as has been reported for p53 (Haupt et al., 1997; Kubbutat
et al., 1997). All of these findings indicate striking similari-
ties in several aspects of p53 and p73 biology.
Unlike the case with p53, hMDM2 interaction did not
target p73 for degradation, since p73 protein levels did not
Figure 3. Irreversible growth inhibition of EJ-p73a and EJ-p73b
cells after induction of p73a or p73b. EJ-p73a or EJ-p73b cells
were seeded directly in (1) tet or (2) tet at 100 cells per 60-mm
plate for indicated time period. After readdition of tet for an-
other 2 wk, colonies visualized by Giemsa staining were counted
and plotted. The percentage of recoverable colonies for each
condition was normalized to the number in (1) tet. All time
points were performed in triplicate.
Figure 4. Cell cycle analysis of EJ-p73a and EJ-p73b cells after
induction of p73a or p73b. Cell cycle analysis was performed as
described in Materials and Methods. BrdU uptake, as measured
by FITC fluorescence, is depicted on the y-axis. DNA content, as
measured by propidium iodide fluorescence, is depicted on the
x-axis. Populations of cells in different phases of the cell cycle are
gated: G0/G1 population (R1), S-phase population (R2), and
G2/M population (R3). The percentage of cells in each gate is in-
dicated for each sample in the table. (A) EJ-p73a, (1) tet. (B)
EJ-p73a, (2) tet, 3 d. (C) EJ-p73b, (1) tet. (D) EJ-p73b, (2)
tet, 3 d.The Journal of Cell Biology, Volume 147, 1999 828
decrease (Fig. 6 A). These results indicate that although
hMDM2 can interact with both p53 and p73, its inhibition
of p73 transcriptional activity is not mediated by a mecha-
nism involving p73 protein degradation. Similar findings
have been reported recently by Zeng et al. (1999).
We observed another major difference in p53 and
p73 biology. In EJ tumor cells in which p53 function had
been inactivated, exogenously expressed p53 but not p73
showed increased protein level in response to several dif-
ferent DNA damaging agents. Since transcription of each
gene was under the control of the same tet-regulatable
promoter, these findings likely reflect p53 protein stabili-
zation in response to genotoxic stress by mechanisms that
remained intact in these tumor cells. The lack of response
of p73 to the same agents further implies differential regu-
lation of these genes at the level of protein stabilization in
these tumor cells. These findings could help to explain a
selective pressure for inactivation of p53 but not p73 func-
tion in the evolution of this tumor despite their compara-
ble ability of inducing permanent growth arrest in these
cells.
We also observed that in MCF7 breast cancer cells with
intact p53, neither endogenous p73a nor p73b was induced
by DNA damaging agents under conditions in which p53
overexpression was readily observed, consistent with a
previous report (Kaghad et al., 1997). Recent studies have
Figure 5. SA-b-gal staining
after p73a or p73b induc-
tion. EJ-p73a or EJ-p73b
cells were maintained in (1)
tet or (2) tet medium. Cells
were washed, fixed, and
stained at pH 6.0 as described
in Materials and Methods.
Cells were photographed us-
ing a Nikon Eclipse TE200
microscope (2003). (A)
EJ-p73a cells, (1) tet, 7 d.
(B) EJ-p73a cells, (2) tet,
7 d. (C) EJ-p73b cells, (2)
tet, 7 d.
Figure 6. Comparison of wild-type and DN-hMDM2 interactions
with p73a or p73b. 293T cells were transfected with HA-tagged
p73a or p73b, together with pcDNA3 vector, hMDM2, or DN-
hMDM2 as indicated at the top of each lane. Western blot analy-
sis was performed either directly with total lysates (A) or after
immunoprecipitation with antibodies as indicated (B).
Figure 7. Wild-type but not NH2-terminal deleted hMDM2 in-
hibits transcriptional activities of p73a and p73b. H1299 cells in
60-mm plates were cotransfected with the plasmids indicated, as
well as the p21 genomic promoter fused to a luciferase reporter
and a b-galactosidase expression vector. At 48 h after transfec-
tion, luciferase activity was measured and the relative units were
plotted. Results of one representative experiment of three inde-
pendently performed assays are shown. Determinations were
made in duplicate for each experimental point.Fang et al. Comparative Analysis of p73 and p53 829
indicated that in mouse embryo fibroblasts, certain other
DNA damaging agents such as cisplatin were able to in-
duce protein stabilization through a mechanism involving
c-Abl (Agami et al., 1999; Gong et al., 1999; Yuan et al.,
1999). We have also observed variation in responsiveness
among different tumor cell lines to p73 induction by DNA
damaging agents (our unpublished observations). Thus,
cell context or the specific agent may be critical determi-
nants of p73 induction in response to DNA damage. Our
present findings that p73 can induce permanent growth ar-
rest, in combination with previous studies that p73 can in-
duce apoptosis in other cells (Jost et al., 1997) imply that
p73 can mimic two major p53 effector functions used in its
role of guardian of the genome. Thus, the paucity of p73
mutations in human tumors may reflect its lack of respon-
siveness to genotoxic stresses which commonly induce p53,
or to a more restricted tissue expression pattern (Senoo et
al., 1998).
We thank Dr. Mourad Kaghad for kindly providing p73 plasmids and Dr.
Zhenqiang Pan for critical reading of the manuscript.
This work was supported in part by National Institutes of Health grant
CA66654 and the T.J. Martell Foundation for Leukemia Cancer and
AIDS Research (to S.A. Aaronson), and National Institutes of Health
grants CA78356 and CA82211 (to S.W. Lee). L. Fang is a recipient of
Forchheimer Foundation Fellowship.
Submitted: 21 July 1999
Revised: 30 September 1999
Accepted: 4 October 1999
References
Agami, R., G. Blandino, M. Oren, and Y. Shaul. 1999. Interaction of c-Abl and
p73a and their collaboration to induce apoptosis. Nature. 399:809–813.
Balint, E., S. Bates, and K.H. Vousden. 1999. Mdm2 binds p73a without target-
ing degradation. Oncogene. 18:3923–3929.
Band, V., S. Dalal, L. Delmolino, and E.J. Androphy. 1993. Enhanced degrada-
tion of p53 protein in HPV-E6 and BPV-1 E6 immortalized human mam-
mary epithelial cells. EMBO (Eur. Mol. Biol. Organ.) J. 12:1847–1852.
Bargonetti, J., I. Reynisdottir, P.N. Friedman, and C. Prives. 1992. Site-specific
binding of wild-type p53 to cellular DNA is inhibited by SV40 T antigen and
mutant p53. Genes Dev. 6:1886–1898.
Brown, D.R., S. Deb, M. Munoz, M.A. Subler, and S.P. Deb. 1993. The tumor
suppressor p53 and the oncoprotein simian virus 40 T antigen bind to over-
lapping domains on the MDM2 protein. Mol. Cell. Biol. 13:6849–6857.
Debbas, M., and E. White. 1993. Wild-type p53 mediates apoptosis by E1A,
which is inhibited by E1B. Genes Dev. 7:546–554.
Di Como, C.J., C. Gaiddon, and C. Prives. 1999. p73 function is inhibited by tu-
mor derived p53 mutants in mammalian cells. Mol. Cell. Biol. 19:1438–1449.
Di Leonardo, A., S.P. Linke, K. Clarkin, and G.M. Wahl. 1994. DNA damage
triggers a prolonged p53-dependent G1 arrest and long term induction of
Cip1 in normal human fibroblasts. Genes Dev. 8:2540–2551.
Dimri, G.P., X. Lee, and G. Basile. 1995. A biomarker that identifies senescent
human cells in culture and in aging skin in vivo. Proc. Natl. Acad. Sci. USA.
92:9363–9367.
Dobbelstein, M., S. Wienzek, C. Konig, and J. Roth. 1999. Inactivation of the
p53-homologue p73 by the mdm2-oncoprotein. Oncogene. 18:2101–2106.
Fang, L., M. Igarashi, J. Leung, M. Sugrue, S. Lee, and S. Aaronson. 1999.
p21Waf1/Cip1/Sdi1 induces permanent growth arrest with markers of repli-
cative senescence in tumor cells lacking functional p53. Oncogene. 18:2789–
2797.
Fields, B.N., D.M. Knipe, and P.M. Howley. 1996. Virology. J.B. Lippincott,
Co., Philadelphia, PA. 3,216 pp.
Gong, J.G., A. Costanzo, H.Q. Yang, G. Melino, W.G.J. Kaelin, M. Levrero,
and J.Y.J. Wang. 1999. The tyrosine kinase c-Abl regulates p73 in apoptotic
response to cisplatin-induced DNA damage. Nature. 399:806–809.
Gossen, M., and H. Bujard. 1992. Tight control of gene expression in mamma-
lian cells by tetracycline-responsive promoters. Proc. Natl. Acad. Sci. USA.
89:5547–5551.
Gottlieb, T.M., and O. Oren. 1996. p53 in growth control and neoplasia. Bio-
chim. Biophys. Acta. 1287:77–102.
Harris, C.C., and M. Hollstein. 1993. Clinical implication of the p53 tumor-sup-
pressor gene. N. Engl. J. Med. 329:1318–1327.
Haupt, Y., R. Maya, A. Kazaz, and M. Oren. 1997. Mdm2 promotes the rapid
degradation of p53. Nature. 387:296–299.
Hollstein, M., K. Rice, M.S. Greenblatt, T. Soussi, R. Fuchs, T. Sorlie, E. Hovig,
B. Smith-Sorensen, R. Montesano, and C.C. Harris. 1994. Database of p53
gene somatic mutations in human tumors and cell lines. Nucleic Acids Res.
22:3551–3555.
Hoppe-Seyler, F., and K. Butz. 1993. Repression of endogenous p53 transacti-
vation function in Hela cervical carcinoma cells by human papillomavirus
type 16 E6, human mdm2, and mutant p53. J. Virol. 67:3111–3117.
Jiang, D., A. Srinivasan, G. Lozano, and P.D. Robbins. 1993. SV40 T antigen
abrogates p53-mediated transcriptional activity. Oncogene. 8:2805–2812.
Jost, C.A., M.C. Marin, and W.G.J. Kaelin. 1997. p73 is a human p53-related
protein that can induce apoptosis. Nature. 389:191–194.
Kaghad, M., H. Bonnet, A. Yang, L. Creancier, J.C. Biscan, A. Valent, A.
Minty, P. Chalon, J.M. Lelias, X. Dumont, et al. 1997. Monoallelically ex-
pressed gene related to p53 at 1p36, a region frequently deleted in neuro-
blastoma and other human cancers. Cell. 90:809–819.
Ko, L.J., and C. Prives. 1996. p53: puzzle and paradigm. Genes Dev. 10:1054–
Figure 8. p73a and p73b proteins are not stabilized by DNA
damage. (A) EJ-p53, EJ-p73a, and EJ-p73b cells were seeded in
medium containing indicated tet concentrations. After 8 h, cells
were treated with DNA damaging agents as indicated at the top
of each lane. 24 h later, lysates were prepared and subjected to
SDS-PAGE. Western blot analysis was performed using anti-p53
and HA antibodies. (B) MCF7 cells were treated with DNA
damaging agents as indicated at the top of each lane. 24 h later,
lysates were subjected to SDS-PAGE. Western blots were per-
formed using anti-p53 or p73 antibodies. EJ-p73a and EJ-p73b in
(2) tet were used as positive controls.The Journal of Cell Biology, Volume 147, 1999 830
1072.
Kubbutat, M.H., S.N. Jones, and K.H. Vousden. 1997. Regulation of p53 stabil-
ity by Mdm2. Nature. 387:299–303.
Lane, D.P., and L.V. Crawford. 1979. T antigen is bound to a host protein in
SV40-transformed cells. Nature. 278:261–263.
Levine, A.J. 1997. p53, the cellular gatekeeper for growth and division. Cell. 88:
323–331.
Levine, A.J., M.C. Wu, A. Chang, A. Silver, E. Attiyeh, J. Lin, and C.B. Ep-
stein. 1995. The spectrum of mutations at the p53 locus. Evidence for tissue-
specific mutagenesis, selection of mutant alleles, and a “gain of function”
phenotype. Ann. N.Y. Acad. Sci. 768:111–128.
Linzer, D.I., and A.J. Levine. 1979. Characterization of a 54K dalton cellular
SV40 tumor antigen present in SV40-transformed cells and uninfected em-
bryonal carcinoma cells. Cell. 17:43–52.
Marin, M.C., C.A. Jost, M.S. Irwin, J.A. DeCaprio, D. Caput, and W.G.J. Kae-
lin. 1998. Viral oncoproteins discriminate between p53 and the p53 homolog
p73. Mol. Cell. Biol. 18:6316–6324.
Mietz, J.A., T. Unger, J.M. Huibregtse, and P.M. Howley. 1992. The transcrip-
tional transactivation function of wild-type p53 is inhibited by SV40 large
T-antigen and by HPV-16 E6 oncoprotein. EMBO (Eur. Mol. Biol. Organ.)
J. 11:5013–5020.
Momand, J., G.P. Zambetti, D.C. Olsen, D. George, and A.J. Levine. 1992. The
mdm-2 oncogene product forms a complex with the p53 protein and inhibits
p53-mediated transactivation. Cell. 69:1237–1245.
Nelson, W.G., and M.B. Kastan. 1994. DNA strand breaks: the DNA template
alterations that trigger p53-dependent DNA damage response pathways.
Mol. Cell. Biol. 14:1815–1823.
Nigro, J.M., S.J. Baker, A.C. Preisinger, J.M. Jessup, R. Hostetter, K. Cleary,
S.H. Bigner, N. Davidson, S. Baylin, P. Devilee, et al. 1989. Mutations in the
p53 gene occur in diverse human tumor types. Nature. 342:705–708.
Oliner, J.D., J.A. Pietenpol, S. Thiagalingam, J. Gyuris, K.W. Kinzler, and B.
Vogelstein. 1993. Oncoprotein MDM2 conceals the activation domain of tu-
mor suppressor p53. Nature. 362:857–860.
Osada, M., M. Ohba, C. Kawahara, C. Ishioka, R. Kanamaru, I. Katoh, Y.
Ikawa, Y. Nimura, A. Nakagawara, M. Obinata, and S. Ikawa. 1998. Cloning
and functional analysis of human p51, which structurally and functionally re-
sembles p53. Nat. Med. 4:839–843.
Rieger, K.M., A.F. Little, J.M. Swart, W.V. Kastrinakis, J.M. Fitzgerald, D.T.
Hess, J.A. Libertino, and I.C. Summerhayes. 1995. Human bladder carci-
noma cell lines as indicators of oncogenic change relevant to urothelial neo-
plastic progression. Br. J. Cancer. 72:683–690.
Roth, J., C. Konig, S. Wienzek, S. Weigel, S. Ristea, and M. Dobbelstein. 1998.
Inactivation of p53 but not p73 by adenovirus type 5 E1B 55-kilodalton and
E4 34-kilodalton oncoproteins. J. Virol. 72:8510–8516.
Scheffner, M., B.A. Werness, J.M. Huibregtse, A.J. Levine, and P.M. Howley.
1990. The E6 oncoprotein encoded by human papillomaviruses types 16 and
18 promotes the degradation of p53. Cell. 63:1129–1136.
Senoo, M., N. Seki, M. Ohira, S. Sugano, M. Watanabe, M. Tachibana, T.
Tanaka, Y. Shinkai, and H. Kato. 1998. A second p53-related protein, p73L,
with high homology to p73. Biochem. Biophys. Res. Commun. 248:603–607.
Sharma, S., I. Schwarte Waldhoff, H. Oberhuber, and R. Schafer. 1993. Func-
tional interaction of wild-type and mutant p53 transfected into human tumor
cell lines carrying activated ras genes. Cell Growth Differ. 4:861–869.
Sugrue, M.M., D.Y. Shin, S.W. Lee, and S.A. Aaronson. 1997. Wild-type p53
triggers a rapid senescence program in human tumor cells lacking functional
p53. Proc. Natl. Acad. Sci. USA. 94:9648–9653.
Trink, B., K. Okami, L. Wu, V. Sriuranpong, J. Jen, and D. Sidransky. 1998. A
new human p53 homologue. Nat. Med. 4:747–748.
Werness, B.A., A.J. Levine, and P.M. Howley. 1990. Association of human
papillomavirus types 16 and 18 E6 proteins with p53. Science. 248:76–79.
Yang, A., M. Kaghad, Y. Wang, E. Gillett, M.D. Fleming, V. Dotsch, N.C. An-
drews, D. Caput, and F. McKeon. 1998. p63, a p53 homolog at 3q27-29, en-
codes multiple products with transactivating, death-inducing, and dominant-
negative activities. Mol. Cell. 2:305–316.
Yew, P.R., and A.J. Berk. 1992. Inhibition of p53 transactivation required for
transformation by adenovirus early E1B protein. Nature. 357:82–85.
Yoshikawa, H., M. Nagashima, M.A. Khan, M.G. McMenamin, K. Hagiwara,
and C.C. Harris. 1999. Mutational analysis of p73 and p53 in human cancer
cell lines. Oncogene. 18:3415–3421.
Yuan, Z.M., H. Shioya, T. Ishiko, X.G. Sun, J.J. Gu, Y.Y. Huang, H. Lu, S.
Kharbanda, R. Weichselbaum, and D. Kufe. 1999. p73 is regulated by ty-
rosine kinase c-Abl in the apoptotic response to DNA damage. Nature. 399:
814–817.
Zeng, X.Y., L.H. Chen, C.A. Jost, R. Maya, D. Keller, X.J. Wang, W.G.J. Kae-
lin, M. Oren, J.D. Chen, and H. Lu. 1999. MDM2 suppress p73 function
without promoting p73 degradation. Mol. Cell. Biol. 19:3257–3266.
Zhu, J., J. Jiang, W. Zhou, and X. Chen. 1998. The potential tumor suppressor
p73 differentially regulates cellular p53 target genes. Cancer Res. 58:5061–
5065.